Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer (MAJA)
Randomized Phase II Study of Vinflunine as Maintenance Monotherapy in Patients With Advanced or Metastatic Urothelial Cancer That Obtains Clinical Benefit of the First Line With Cisplatin-gemcitabine Combination
Sponsor: Spanish Oncology Genito-Urinary Group
Listed as NCT01529411, this PHASE2 trial focuses on Carcinoma, Transitional Cell and remains completed. Sponsored by Spanish Oncology Genito-Urinary Group, it has been updated 7 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
May 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — May 2019 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Spanish Oncology Genito-Urinary Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alcorcón, Spain , Badalona, Spain , Barcelona, Spain , Ciudad Real, Spain , Elda, Spain , L'Hospitalet de Llobregat, Spain , Madrid, Spain , Manresa, Spain , Palma de Mallorca, Spain , Pamplona, Spain and 4 more locations